

DESCRIPTION

Source Mouse myeloma cell line, NS0-derived mouse MMP-7 protein
Met1-Leu264
Accession # AAA99983

N-terminal Sequence Analysis Leu18

Structure / Form Pro form

Predicted Molecular Mass 28 kDa

SPECIFICATIONS

SDS-PAGE 31 kDa, reducing conditions

Activity Measured by its ability to cleave a fluorogenic peptide substrate Mca-KPLGL-Dpa-AR-NH₂ (Catalog # ES010).
The specific activity is >2000 pmol/min/μg, as measured under the described conditions.

Endotoxin Level <1.0 EU per 1 μg of the protein by the LAL method.

Purity >90%, by SDS-PAGE under reducing conditions and visualized by silver stain.

Formulation Supplied as a 0.2 μm filtered solution in MES, NaCl, CaCl₂ and Glycerol. See Certificate of Analysis for details.

Activity Assay Protocol

Materials

- Assay Buffer: 50 mM Tris, 10 mM CaCl₂, 150 mM NaCl, 0.05% (w/v) Brij-35, pH 7.5 (TCNB)
- Recombinant Mouse MMP-7 (rmMMP-7) (Catalog # 2967-MP)
- p-aminophenylmercuric acetate (APMA) (Sigma, Catalog # A-9563), 100 mM stock in DMSO
- Substrate: MCA-Lys-Pro-Leu-Gly-Leu-DPA-Ala-Arg-NH₂, (Catalog # ES010)
- F16 Black Maxisorp Plate (Nunc, Catalog # 475515)
- Fluorescent Plate Reader (Model: Gemini EM by Molecular Devices) or equivalent

Assay

1. Dilute rmMMP-7 to 100 μg/mL in Assay Buffer.
2. Activate rmMMP-7 by adding APMA to a final concentration of 1 mM.
3. Incubate at 37 °C for 1 hour.
4. Dilute activated rmMMP-7 to 0.4 ng/μL in Assay Buffer.
5. Dilute Substrate to 120 μM in Assay Buffer.
6. In a plate, load 50 μL of 0.4 ng/μL rmMMP-7 and start the reaction by adding 50 μL of 120 μM Substrate. Include a Substrate Blank containing 50 μL Assay Buffer and 50 μL of 120 μM Substrate.
7. Read at excitation and emission wavelengths of 320 nm and 405 nm (top read), respectively in kinetic mode for 5 minutes.
8. Calculate specific activity:

$$\text{Specific Activity (pmol/min/μg)} = \frac{\text{Adjusted } V_{\max}^* \text{ (RFU/min)} \times \text{Conversion Factor}^{**} \text{ (pmol/RFU)}}{\text{amount of enzyme (μg)}}$$

*Adjusted for Substrate Blank

**Derived using calibration standard MCA-Pro-Leu-OH (Bachem, Catalog # M-1975).

Final Assay Conditions

Per Well:

- rmMMP-7: 0.020 μg
- Substrate: 60 μM

PREPARATION AND STORAGE

Shipping The product is shipped with dry ice or equivalent. Upon receipt, store it immediately at the temperature recommended below.

Stability & Storage Use a manual defrost freezer and avoid repeated freeze-thaw cycles.

- 6 months from date of receipt, -20 to -70 °C as supplied.
- 3 months, -20 to -70 °C under sterile conditions after opening.

BACKGROUND

Matrix metalloproteinases (MMPs) are a family of zinc and calcium dependent endopeptidases with the combined ability to degrade all the components of the extracellular matrix. MMP-7 (matrilysin) is expressed in epithelial cells of normal and diseased tissues, and is capable of digesting a large series of proteins of the extracellular matrix including collagen IV and X, gelatin, casein, laminin, aggrecan, entactin, elastin and versican (1). MMP-7 is implicated in the activation of other proteinases such as plasminogen, MMP-1, MMP-2, and MMP-9. In addition to its roles in connective tissue remodeling and cancer, MMP-7 also regulates intestinal α-defensin activation in innate host defense, releases tumor necrosis factor-α in a model of herniated disc resorption, and cleaves FasL to generate a soluble form in a model of prostate involution. Structurally, MMP-7 is the smallest of the MMPs and consists of two domains: a pro-domain that is cleaved upon activation and a catalytic domain containing the zinc-binding site.

References:

1. Woessner, J.F. (2004) in *Handbook of Proteolytic Enzymes*, Barrett, A.J. et al. eds. p. 532.